Bourdeau Isabelle, Lacroix André, Schürch Walter, Caron Philippe, Antakly Tony, Stratakis Constantine A
Division of Endocrinology and Pathology, Hôtel-Dieu du Centre Hospitalier de l'Université de Montréal and Department of Biochemistry, Université de Montréal, Montréal, Canada H2W 1T7.
J Clin Endocrinol Metab. 2003 Aug;88(8):3931-7. doi: 10.1210/jc.2002-022001.
Primary pigmented nodular adrenocortical disease (PPNAD) is a rare cause of ACTH-independent adrenal Cushing's syndrome (CS), which is often associated with Carney complex (CNC). We have recently described a paradoxical increase in cortisol excretion after dexamethasone administration in most patients with PPNAD. In the present study we investigated the hypothesis that this phenomenon is due to a primary abnormality of the tissues affected by PPNAD, rather than a defect of the patients' hypothalamic-pituitary-adrenal axis; as such it should be replicated in vitro by adrenal slices exposed directly to dexamethasone. We were able to study adrenal tissues from eight patients with CS caused by PPNAD; two patients were also studied in vivo according to a protocol first described in ACTH-independent macronodular adrenal hyperplasia (AIMAH) for the clinical detection of aberrant hormone receptor expression. Their DNA has been previously screened for inactivating mutations of the PRKAR1A gene, the most frequent molecular defect leading to PPNAD and/or CNC. We also investigated whether glucocorticoid receptor (GR) expression underlies paradoxical dexamethasone responses in PPNAD by immunohistochemistry and semiquantitative PCR, and we correlated GR expression with that of other markers for PPNAD (e.g. synaptophysin). Indeed, we demonstrated that dexamethasone induced cortisol secretion in vitro in five of these tumors; no such increase was seen in adenomatous or AIMAH tissues that were treated in the same manner. GR mRNA was expressed, and GR immunoreactivity was detected in PPNAD nodular cells. Staining for GR was not seen in surrounding cortical cells, and hence, it correlated with synaptophysin, which also stains PPNAD in a similar manner. In normal adrenal tissue, GR was detected mostly in medullary areas, whereas GR immunoreactivity was weak in adenomatous and AIMAH tissues. We conclude that 1) dexamethasone produces an increase in glucocorticoid synthesis by PPNAD adrenal slices in vitro, suggesting a direct effect on adrenocortical tissue, and 2) this phenomenon is accompanied by increased expression of the GR in PPNAD nodules. PPNAD and/or CNC patients with and without mutations leading to protein kinase A activation demonstrated in vitro and/or in vivo paradoxical dexamethasone responses and GR expression, indicating that PRKAR1A alterations are not necessary for these phenomena.
原发性色素沉着性结节性肾上腺皮质疾病(PPNAD)是促肾上腺皮质激素(ACTH)非依赖性肾上腺库欣综合征(CS)的罕见病因,常与卡尼综合征(CNC)相关。我们最近描述了大多数PPNAD患者在给予地塞米松后皮质醇排泄出现反常增加的现象。在本研究中,我们探讨了这一现象是由于PPNAD所累及组织的原发性异常,而非患者下丘脑 - 垂体 - 肾上腺轴缺陷的假说;因此,直接暴露于地塞米松的肾上腺切片在体外应能重现这一现象。我们得以研究8例由PPNAD导致CS的患者的肾上腺组织;根据最初在ACTH非依赖性大结节性肾上腺增生(AIMAH)中描述的用于临床检测异常激素受体表达的方案,对其中2例患者也进行了体内研究。此前已对他们的DNA进行筛查,以寻找PRKAR1A基因的失活突变,这是导致PPNAD和/或CNC最常见的分子缺陷。我们还通过免疫组织化学和半定量PCR研究了糖皮质激素受体(GR)表达是否是PPNAD中地塞米松反常反应的基础,并将GR表达与PPNAD的其他标志物(如突触素)的表达进行了关联。事实上,我们证明地塞米松在体外可诱导其中5个肿瘤分泌皮质醇;以同样方式处理的腺瘤或AIMAH组织中未见这种增加。GR mRNA有表达,并且在PPNAD结节细胞中检测到GR免疫反应性。在周围皮质细胞中未见GR染色,因此,它与突触素相关,突触素也以类似方式对PPNAD进行染色。在正常肾上腺组织中,GR主要在髓质区域检测到,而在腺瘤和AIMAH组织中GR免疫反应性较弱。我们得出结论:1)地塞米松在体外可使PPNAD肾上腺切片的糖皮质激素合成增加,提示对肾上腺皮质组织有直接作用;2)这一现象伴随着PPNAD结节中GR表达增加。有和没有导致蛋白激酶A激活突变的PPNAD和/或CNC患者在体外和/或体内均表现出地塞米松反常反应和GR表达,表明PRKAR1A改变对于这些现象并非必需。